Non Muscle Invasive Bladder Cancer, Treatment by BCG
Conditions
Brief summary
Intravesical BCG immunotherapy is used after transurethral resection (TUR) for the prevention of recurrence of NMIBC. BCG treatment is usually started a few weeks after TUR and is given once a week for 6 weeks. It stimulates immune responses that can destroy bladder cancer cells (acute and chronic induced inflammations) and as a consequence causes side effects. The investigators postulate that Xpert® test might be used to demonstrate the presence of residual (after TURB) or recurrent (during adjuvant treatment) disease at the time of intravesical treatment, which could be of very significant impact in the management of this complex situation.Urines of BCG treated patients are rich in immune system elements (cytokines, lymphocytes,…), this complex inflammatory milieu of urines may interfere with urinary biomarkers. This study will allow assessing the effect of the complex inflammatory milieu induced by BCG treatment in urines of patients with NMIBC on the Xpert® Bladder cancer assay.
Detailed description
1. Qualification of Xpert® Testing: Three 50 mL fresh urine samples will be collected in sterile containers according to Cepheid instructions of use: * the baseline sample before the first BCG instillation, * the study sample taken during the initiation course of treatment instillations, preferably at the 4th or 5th instillation of BCG therapy, * the follow-up sample at the time of the first follow-up cystoscopy, approximately 3 months after the last BCG instillation of the initiation course. Xpert® test results will be qualified as positive or negative, according to Cepheid instructions for use. Samples tested positive at baseline will not be included in the analysis and the patient's participation in the study will be discontinued. Samples obtained in patients with no recurrence at follow-up cystoscopy after the initiation course will be considered for analysis. 2. Threshold of detection of theXpert® Bladder test: * One urine sample of a patient tumor free (negative Xpert test) under BCG treatment will be spiked into 3 log dilutions of the 2 distinct tumor cell lines SW780 and BE(2)-C (100, 1000, and 10000 cells per ml). * A mix of fresh and frozen cells from en bloc harvested tumors from distinct donors will be tested at the set concentration in BCG urines from distinct patients.
Interventions
BIOLOGICALXpert bladder Test
Xpert test positive or negative on urine samples of NMIBC patients treated by BCG
Sponsors
Cepheid
Institut Claudius Regaud
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients presenting with high-risk transitional cell carcinoma of the bladder, according to the EAU guidelines/EORTC risk stratification, who are offered adjuvant BCG instillations.
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of negative Xpert tests results during the initiation course in patients with no recurrence at first follow-up cystoscopy | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| rate of Xpert tests found positive in samples with predefined tumour cell concentrations ( limit of detection) in inflammatory milieu of urines induced by the BCG treatment in patients with bladder cancer | 12 months |
Countries
France
Contacts
Primary ContactPhilipppe ROCHAIX, MD
Outcome results
None listed